Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer
Molecular Omics · 2024
DOI: 10.1039/d4mo00147h ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, 2024. Verfasst von Irene A George und 7 weiteren Autor:innen. Beteiligte Einrichtung: Manipal Academy of Higher Education (MAHE), Manipal, 576104, Karnataka, India. Hauptthemen laut MEDLINE: Cisplatin, Uterine Cervical Neoplasms, Proteomics, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cisplatin-based concurrent chemoradiotherapy (CCRT) is the standard treatment for cervical patients with locally advanced disease. Despite the improved survival rates and prognosis observed in patients undergoing CCRT, over 30–40% do not achieve complete response and are at risk of locoregional recurrence. Targeting crucial molecules that confer resistance may improve the clinical outcomes of the treatment resistant patient cohort. Herein, we employed a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based phosphoproteomic approach to identify the altered phosphophorylation events, activated kinases and dysregulated pathways involved in treatment resistance. We quantified 2531 unique phosphopeptides mapping to 1099 proteins of which 74 proteins were differentially phosphorylated between the cohorts. Pathway analysis revealed dysregulation of the DNA repair pathway and the proteins involved in DNA repair in the non-responder cohort. Additionally, we identified kinase signature associated with CCRT resistance. Kinases such as CSNK2A1, PRKDC, PLK-1, NEK2, ATM and CDK1 are predicted to be activated in non-responders. In particular, we showed that CSNK2A1 is involved in oncogenesis of cervical cancer and pharmacological inhibition led to reduced cell proliferation, migration and colony formation. Moreover, the combination of the CSNK2A1 inhibitor, silmitasertib with cisplatin demonstrated synergism (combination index < 1) and yielded a beneficial reduction in dosage. The dose reduced combination potentially reduced the proliferative, migratory and colony formation ability in vitro. Our findings highlight the potential of phosphoproteomics to identify clinically significant targets and pathways implicated in CCRT resistance. Our study also indicates that combination therapy could serve as an effective treatment strategy to improve the efficacy of patients undergoing CCRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Manipal Academy of Higher Education (MAHE), Manipal, 576104, Karnataka, India.
- Institute of Bioinformatics, Bangalore, 560066, Karnataka, India. prashant@ibioinformatics.org.
- Vedantaa Hospital & Research Centre, Palghar, 401606, Maharashtra, India.
- Mahavir Cancer Sansthan and Research Centre (MCSRC), Patna, 801505, Bihar, India. chauhan_richa@outlook.com.
- Karkinos Foundation, Mumbai, 400086, Maharashtra, India.
- Karkinos Healthcare Pvt Ltd, Navi Mumbai, 400705, Maharashtra, India.
Zitieren
APA
George, I. A., Sambath, J., Dhawale, R. E., Singh, M., Trivedi, V., Venkataramanan, R., Chauhan, R., & Kumar, P. (2024). Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer. Molecular Omics. https://doi.org/10.1039/d4mo00147h
Vancouver
George IA, Sambath J, Dhawale RE, Singh M, Trivedi V, Venkataramanan R, et al. Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer. Molecular Omics. 2024. doi:10.1039/d4mo00147h
BibTeX
@article{George2024,
author = {George, Irene A and Sambath, Janani and Dhawale, R E and Singh, Manisha and Trivedi, Vinita and Venkataramanan, R and Chauhan, Richa and Kumar, Prashant},
title = {Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer},
journal = {Molecular Omics},
year = {2024},
doi = {10.1039/d4mo00147h}
}
EUVIMED